1408327-48-9

Upstream product

• 74-89-5 methylamine 
• 109-83-1 (2-hydroxyethyl)(methyl)amine 
• 198348-89-9 5-nitropyrazole-3-carboxylic acid 
• 4535-90-4 N-methyl-2-chloroethylamine hydrochloride 

Downstream Products

• 1227210-32-3 5-methyl-2-nitro-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine 
• 1227210-33-4 5-methyl-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazin-2-yl-amine 

Relevant academic research and scientific papers

Focal adhesion kinase inhibitor and use

The invention belongs to the field of medicines, relates to a focal adhesion kinase inhibitor and use, in particular relates to a novel focal adhesion kinase inhibitor compound, or stereoisomers, geometric isomers, tautomers, oxynitrides, hydrates, solvates, metabolites, pharmaceutically acceptable salts or prodrugs thereof, further relates to the use of the compound and pharmaceutical compositions as medicines, in particular the use of the compound and pharmaceutical compositions in manufacture of medicines for treatment or prevention of cancer, pulmonary hypertension, and pathological angiogenesis-related diseases.

CHEMICAL COMPOUNDS AS INHIBITORS OF INTERLEUKIN-1 ACTIVITY

The present disclosure relates to novel sulfonylurea and sulfonyl thiourea compounds and related compounds and their use in treating a disease or condition responsive to modulation of cytokines such as IL-1β and IL-18, modulation of NLRP3 or inhibition of the activation of NLRP3 or related components of the inflammatory process.

A concise synthesis of a tetrahydropyrazolopyrazine building block

A concise synthesis of a tetrahydropyrazolopyrazine building block is described. 5-Methyl-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazin-2-ylamine was prepared in three steps and 80% yield from 5-nitro-2H-pyrazole-3-carboxylic acid. This compound was then coupled with 4-bromo-6-chloro-2-methyl-2H- pyridazin-3-one in the presence of sodium tert-pentoxide to give the target product in 87% yield. The process was successfully scaled up to a multihundred gram scale.